ClinicalTrials.gg
CompletedNCT02612129Updated Nov 29, 2024Results posted

Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C

A Phase 2/3 interventional study of arimoclomol and Placebo in Niemann-Pick Disease, Type C, sponsored by ZevraDenmark. Completed at 14 sites in 9 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2024-11-29.

Sponsored by ZevraDenmark · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 23 studies in Niemann-Pick Disease, Type C with a site in United States — 6 open to participants now, 8 under way, 4 of them phase 3. Niemann-Pick Disease, Type C · United States.

Enrollment
7th of 17
50 · median 33
Started
2016
the only one that year
Phase 2/3
3 of 23
none open now
Registered
8th of 23
by date
Lead sponsor
2 of 23
ZevraDenmark

Among the 23 studies in Niemann-Pick Disease, Type C with a site in United States, this one is the 7th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2016, is one of 3 in phase 2/3, and was the 8th registered.

Niemann-Pick Disease, Type C

37 studies on the registry are indexed under Niemann-Pick Disease, Type C; 8 are open to participants now.

Browse Niemann-Pick Disease, Type C studies →

Open to participants now

6 of the 23 studies in Niemann-Pick Disease, Type C with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Niemann-Pick Disease, Type C studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Niemann-Pick Disease, Type C with a site in United States, or all of them as a file.
02

Study summary

A prospective, randomized, double-blind, placebo controlled therapeutic study in participants with confirmed diagnosis of Niemann-Pick disease type C (NPC).

The purpose of this study is to assess the efficacy and safety of arimoclomol (compared to placebo) when it is administered as an add-on therapy to the participant's current prescribed best routine clinical care; participant's routine clinical care may, or may not, include miglustat.

The CT-ORZY-NPC-002 study has been expanded to include an open label paediatric sub-study including participants aged 6 to \<24 months at study enrolment.

Read the detailed description

A prospective, randomized, double-blind, placebo controlled therapeutic study in participants with confirmed diagnosis of Niemann-Pick disease type C (NPC).

Participants must either 1) have completed Visit 2 (end of study [EOS]) of the CT-ORZY-NPC-001 study or 2) meet the eligibility criteria of this study including a requirement of stable treatment with miglustat for 6 months (if on miglustat therapy) prior to enrolment into the study.

Aim:

The purpose of this study is to assess the efficacy and safety of arimoclomol (compared to placebo) when it is administered as an add-on therapy to the participant's current prescribed best routine clinical care; participant's routine clinical care may, or may not, include miglustat.

Randomization:

Participants will be randomized to receive placebo or arimoclomol (with an allocation ratio of 1:2).

Pharmacokinetic evaluation (age below 12):

To confirm the selected dose, participants less than 12 years of age will undergo an arimoclomol single-dose pharmacokinetic (PK) evaluation before randomization and the start of continuous (multiple dosing) treatment.

Early Escape Clause:

In participants whose disease progression is too severe and/or too fast, the "early escape clause" will allow the Investigator to apply the escape route which implies that the participant can be treated with arimoclomol (as per blinded phase study schedule) and be followed up according to the study schedule or until the analysis of data from the controlled, 12-month blinded phase study period does not support the efficacy and/or safety of arimoclomol.

Study duration:

The duration of the blinded phase study period will be 12-months.

Following this, all participants will be offered to continue into the extension phase of the study where every participant will receive arimoclomol and be followed up and attend site visits every 6 months until 60 months after randomization. The extension phase runs until arimoclomol has received Regulatory Approval or until the analysis of data from the controlled, blinded phase 12-month study period does not support the efficacy and/or safety of arimoclomol.

The CT-ORZY-NPC-002 protocol has been updated to include a paediatric sub-study including new and naïve participants aged 6 to \<24 months at study enrolment.

Aim:

The purpose of the paediatric sub-study, is to assess the safety and tolerability of 36 months of open-label arimoclomol when administered as an add-on therapy to the participant's current prescribed best routine clinical care; participant's routine clinical care may, or may not, include miglustat.

The Paediatric sub-study will run at the open sites participating in the main study. A total of 3-5 participants are planned to be enrolled. All participants will be treated with arimoclomol.

Main Inclusion Criteria:

  • Diagnosis of NPC1 or NPC2;
  • NPC diagnosis confirmed by:

    • Genetically confirmed (deoxyribonucleic acid [DNA] sequence analysis) by mutations in both alleles of NPC1 or NPC2, OR
    • Mutation in only one allele of NPC1 or NPC2 plus either positive filipin staining or elevated cholestane triol/oxysterols (>2 x upper limit of normal).
  • Males and females aged 6 to \<24 months, with a cap of maximum 3 participants above 18 months
  • Treated or not treated with miglustat;

    • If a participant is on prescribed treatment with miglustat, the dose must have been stable for at least 1 month prior to inclusion in the paediatric sub-study
    • If a participant has been discontinued from prescribed treatment with miglustat, they must have been discontinued for at least 1 month prior to inclusion in the paediatric sub-study
  • The Legal Authorised Representative (LAR) has read and signed the Informed Consent Form (ICF) prior to any study-related procedures
  • The LAR agrees for the participant to participate in all aspects of the trial design

Main Exclusion Criteria:

  • Recipient of a liver transplant or a planned liver transplant
  • The Aspartate Transaminase (AST) and/or Alanine Transaminase (ALT) >3 x Upper Limit of Normal (ULN) for age and gender
  • Renal insufficiency with serum creatinine level >1.5 x ULN
  • Participants with known causes of active liver disease or prolonged icterus or malformation of organs other than NPC
  • Participant was born before 37 weeks of gestation
  • Participant weight \<5 kg at study enrollment
  • Participant is diagnosed with severe intra-uterine growth restriction
  • Participant has severe neurological symptoms
  • Participant has received or plans to receive a bone marrow transplant

Arms and Intervention:

1 arm open label treatment with arimoclomol capsules 100 mg (dispersed in water) for oral administration (3 times daily). Doses: The dose in mL is based on the participant's weight in kg.

Randomization: Open Label

Pharmacokinetic: To confirm the selected dose, participants will undergo an arimoclomol single-dose pharmacokinetic (PK) evaluation before the start of continuous treatment.

Visit schedule time frame: Screening (V1); enrollment Week 1 (V2 baseline), Weeks 2 (V3), continuing visits at months 1 (V4), 3 (V5), 6 (V6), 9 (V7), 12 (V8), 15 (V8a), 18 (V9), 24 (V10), 30 (V11) and 36 (V12).

Primary objective: Safety and tolerability

Main Endpoint measures:

Safety data: Adverse events (AEs); Vital signs; Hematology; Clinical chemistry

Clinical status data: Clinical signs and symptoms captured through physical examination; Change from baseline in patient weight and height; Change in Bayley III score: Developmental delay scoring

Imaging data: Changes from baseline in the size of the liver and spleen assessed by ultrasound

03

Conditions studied

  • Niemann-Pick Disease, Type C

Keywords

  • NPC1
  • Niemann-Pick Type C
  • Niemann-Pick
  • arimoclomol
  • lysosomal storage disorder
  • lysosomal storage disease
  • NPC2
  • NP-C
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

EITHER NP-C participants who have entered the CT-ORZY-NPC-001 study and who have completed Visit 2 (EOS) of the CT-ORZY-NPC-001 study.

OR

NPC participants who did not enter or complete the CT-ORZY-NPC-001 study but are fulfilling all of criteria listed below:

◦Diagnosis of NPC1 or NPC2;

NPC diagnosis confirmed by:

  • Genetically confirmed (deoxyribonucleic acid [DNA] sequence analysis) by mutations in both alleles of NPC1 or NPC2, OR
  • Mutation in only one allele of NPC1 or NPC2 plus either positive filipin staining or elevated cholestane triol/oxysterols (>2 x ).

    • Males and females aged from 2 years to 18 years and 11 months;
    • Treated or not treated with miglustat;
    • If a participant is under prescribed treatment with miglustat, it has to be under stable dose of the medication for at least 6 continuous months prior to inclusion in the CT-ORZY-NPC-002 study;

      o If a participant has been discontinued from prescribed treatment with miglustat, they must have been discontinued for at least 3 continuous months prior to inclusion in the CT-ORZY-NPC-002 study;

    • (BMI) Z score ≥ -2 SD (standard deviation) for age, according to the World Health Organisation (WHO) standards;
    • Presenting at least one neurological symptom of the disease (for example, but not limited to, hearing loss, vertical supranuclear gaze palsy, ataxia, dementia, dystonia, seizures, dysarthria, or dysphagia);
    • Ability to walk either independently or with assistance.

      • Written (and assent if appropriate to local laws and regulations) prior to any study-related procedures;
      • Willing to participate in all aspects of trial design including blood sampling (PK, blood biomarkers and safety labs), skin and imaging (ultrasonography of the liver and spleen);
      • Ability to travel to the corresponding clinical trial site at the scheduled visit times for evaluation and follow-up;
      • All sexually active female participants of (post-menarchal) must use highly effective during the study and until 1 week after the last dose of IMP.

Highly effective birth control methods include: Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable); intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; and vasectomised partner.

All sexually active male participants with female partners of child-bearing potential (post-menarchal) must use a condom with or without spermicide in addition to the birth control used by their partners during the study and until 3 months after the last dose of IMP.

Sexual abstinence is considered a highly effective birth control method only if it is defined as refraining from heterosexual intercourse during the study and for 1 week after the last dose of IMP (for female participants of child-bearing potential) and for 3 months after the last dose of IMP (for male participants with female partners of child-bearing potential). The reliability of sexual abstinence needs to be evaluated by the Investigator in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant.

•Ability to comply with the protocol-specified procedures/evaluations and scheduled visits.

Exclusion criteria

Exclusion Criteria:

  • Recipient of a liver transplant or planned liver transplantation;
  • Severe liver insufficiency (defined as hepatic laboratory parameters, and/or ALT greater than three-times the for age and gender (central laboratory assessment);
  • Renal insufficiency, with serum creatinine level greater than 1.5 times the upper limit of normal (central laboratory assessment);
  • Known or suspected allergy or intolerance to the IMP (arimoclomol or constituents);
  • In the opinion of the Investigator, the participant's clinical condition does not allow for the required blood collection and/or skin as per the protocol-specified procedures;
  • Treatment with any drug during the study or in the 4 weeks prior to entering the study.

This includes treatment with any investigational drug during the study in an attempt to treat NP-C;

  • Pregnancy or breastfeeding;
  • Current participation in another trial is not permitted unless it is a non-interventional study and the sole purpose of the trial is for long-term follow up/survival data (registry);
  • For participants who have not completed the CT-ORZY-NPC-001 study, fulfilling any of the criteria listed below:

    • Participants with uncontrolled severe epileptic seizures period (at least 3 consecutive severe epileptic seizures that required medication) within 2 months prior to the written consent. This includes participants with ongoing seizures that are not stable in frequency or type or duration over a 2 month period prior to enrolment, requiring change in dose of antiepileptic medication (other than adjustment for weight) over a 2 month period prior to enrolment, or requiring 3 or more antiepileptic medications to control seizures;
    • Neurologically asymptomatic participants;
    • Severe manifestations of NP-C disease that would interfere with the participant's ability to comply with the requirements of this protocol;
    • Treatment with any IMP within 4 weeks prior to the study enrolment.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Arimoclomol Single PK Dose

    Participants less than 12 years received a single oral dose of arimoclomol capsule, based on participant's body weight, on Day 1.

    Drug: arimoclomol

  • Experimental
    Arimoclomol (12-month Double-blind Phase)

    Participants received arimoclomol capsules orally three times a day (TID) for 12 months. The dose was 31-124 mg arimoclomol base TID (equivalent to 50-200 mg arimoclomol citrate TID), based on participant's body weight.

    Drug: arimoclomol

  • Placebo comparator
    Placebo (12-month Double-blind Phase)

    Participants received matching placebo capsules (with regard to weight, appearance, smell, flavor etc.) orally TID for 12 months.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Niemann-Pick Disease Type C (NPC) Disease Severity Assessed Based on the 5-domain NPCCSS Total Scores

    NPC disease severity was assessed based on the 5-domain NPC Clinical Severity Scale (NPCCSS). The 5-domain NPCCSS focuses on domains identified by participants, caregivers, and NPC experts as the most clinically relevant when assessing disease progression in NPC: Ambulation, fine motor skills, swallow, cognition, and speech. The scale is derived from the original 17-domain NPCCSS. Each domain is rated on a scale of 0-5 based on clinical assessments, observations, and interviews with participants/caregiver. The total score is a sum of the score of each of the 5 domains and ranges from 0-25, with a higher score indicating more severe clinical impairment.

    Time frame: Baseline to Month 12

Secondary outcomes

  1. Percentage of Responders in Clinical Global Impression Scale of Improvement (CGI-I) - Defined as Percentage of Participants Where the CGI-I Score Remains Stable or Shows Improvement (This Outcome Measure Was Considered Co-primary by the FDA)

    The CGI-I is a 7-point scale that rates total improvement of participant's condition. The clinician rates the participants from 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, or 7=Very much worse. Scores thus range from 1-7 with lower scores indicating greater improvement. Responders were the participants with a score of 1 or 2 at Month 12.

    Time frame: Month 12

  2. Percentage of Responders in 5-domain NPCCSS - Defined as Participants Where the 5-domain NPCCSS Score Remains Stable or Improves as Compared to Baseline

    NPC disease severity was assessed based on the 5-domain NPC Clinical Severity Scale (NPCCSS). The 5-domain NPCCSS focuses on domains identified by participants, caregivers, and NPC experts as the most clinically relevant when assessing disease progression in NPC: Ambulation, fine motor skills, swallow, cognition, and speech. The scale is derived from the original 17-domain NPCCSS. Each domain is rated on a scale of 0-5 based on clinical assessments, observations, and interviews with participants/caregiver. The total score is a sum of the score of each of the 5 domains and ranges from 0-25, with a higher score indicating more severe clinical impairment. Stable was defined as a participant's total score for the 5 domains being the same at month 12 as at baseline. Improvement was defined as a participant's total score at month 12 being lower than at baseline.

    Time frame: Baseline to Month 12

  3. Time to Worsening

    Time to worsening was defined as the time until the participant reached the predefined minimal clinically important difference (MCID) of 2 points compared to baseline on the 5-domain NPC Clinical Severity Scale (NPCCSS). The 5-domain NPCCSS focuses on domains identified by participants, caregivers, and NPC experts as the most clinically relevant when assessing disease progression in NPC: Ambulation, fine motor skills, swallow, cognition, and speech. The scale is derived from the original 17-domain NPCCSS. Each domain is rated on a scale of 0-5 based on clinical assessments, observations, and interviews with participants/caregiver. The total score is a sum of the score of each of the 5 domains and ranges from 0-25, with a higher score indicating more severe clinical impairment. The values reported per group are the 25th percentile Kaplan-Meier estimates and 95% confidence interval.

    Time frame: Baseline to Month 12

  4. Percentage of Participants With Worsening

    Worsening was defined as participants that have reached the predefined MCID of 2 points on their 5-domain NPC Clinical Severity Scale (NPCCSS). The 5-domain NPCCSS focuses on domains identified by participants, caregivers, and NPC experts as the most clinically relevant when assessing disease progression in NPC: Ambulation, fine motor skills, swallow, cognition, and speech. The scale is derived from the original 17-domain NPCCSS. Each domain is rated on a scale of 0-5 based on clinical assessments, observations, and interviews with participants/caregiver. The total score is a sum of the score of each of the 5 domains and ranges from 0-25, with a higher score indicating more severe clinical impairment.

    Time frame: Months 6 and 12

  5. Change From Baseline in 17-domain NPCCSS Apart From Hearing Domains (i.e. Hearing and Auditory Brainstem Response)

    The NPC Clinical Severity Scale (NPCCSS) is a disease-specific, clinician-reported outcome measure developed to characterize and quantify NPC disease progression. The 17-domain NPCCSS includes clinical signs and symptoms in nine major and eight minor domains, which are rated on scales of 0-5 (for the major domains) or 0-2 (for the minor domains). The total score is the sum of the score of each of the 17 domains and ranges from 0 to 61, with a high score indicating a more severe clinical impairment.

    Time frame: Baseline to 6 and 12 months

  6. Change From Baseline in 5-domain NPCCSS Score

    The 5-domain NPC Clinical Severity Scale (NPCCSS) focuses on domains identified by participants, caregivers, and NPC experts as the most clinically relevant when assessing disease progression in NPC: Ambulation, fine motor skills, swallow, cognition, and speech. The scale is derived from the original 17-domain NPCCSS. Each domain is rated on a scale of 0-5 based on clinical assessments, observations, and interviews with participants/caregiver. The total score is a sum of the score of each of the 5 domains and ranges from 0-25, with a higher score indicating more severe clinical impairment.

    Time frame: Baseline to 6 months

  7. Changes From Baseline in Each Individual Domain of the NPCCSS

    The NPC Clinical Severity Scale (NPCCSS) is a disease-specific, clinician-reported outcome measure developed to characterize and quantify disease progression. The 17-domain NPCCSS includes clinical signs and symptoms in nine major (ambulation, cognition, eye movement, fine motor, hearing, memory, seizures, speech, swallowing,) and eight minor (auditory brainstem response, behavior, gelastic cataplexy, hyperreflexia, incontinence, narcolepsy, psychiatric, respiratory problems) domains, which are rated on scales of 0-5 (for the major domains) or 0-2 (for the minor domains). A higher score indicates a more severe clinical impairment.

    Time frame: Baseline to 6 and 12 months

  8. Change From Baseline in the NPC Clinical Database (NPC-CDB) Score (Modified "Stampfer Score")

    The NPC Clinical Database (NPC-cdb) score aims to reflect the current clinical status of the participant. The NPC-cdb score represents both historical symptoms and a current status. The test consists of ten areas: visceral signs, development, motor function, ocular-motor abnormalities, seizures/cataplexy/narcolepsy, cognitive abilities and memory, behavioral and psychiatric abnormalities, speech, hearing, and abilities in daily life. The current status score is a severity-weighted sum of 72 symptoms considered as disease-relevant at the time of assessment. Each symptom contributes with a score between 1 and 5, the maximum score is 125. An increase in score reflects a reduction in the participant's abilities.

    Time frame: Baseline to 6 and 12 months

  9. Percentage of Participants With Change From Baseline in Quality of Life (EQ-5D-Y)

    The EQ-5D-Y descriptive system includes 5 descriptive items: Mobility, self-care, doing usual activities, having pain or discomfort, and feeling anxiety or depressed. Each dimension has 3 levels: No problems, some problems, and a lot of problems. The change in the 5 individual items of the EQ-5D-Y per participant was explored by using the pareto principle at 6 and 12 months to show the number (%) of participants who felt: * Better (better on at least one dimension and no worse in any other dimension), * Worse (worse in at least one dimension, and no better in any other dimension)

    Time frame: Baseline to 6 and 12 months

  10. Change From Baseline in the Scale for Assessment and Rating of Ataxia (SARA) Score

    The SARA included eight items reflecting neurologic manifestations of cerebellar ataxia. The test provides a direct and simple description of motor function in a participant. The test consists of 8 test items: gait, stance, sitting, speech disturbance, finger chase, nose-finger test, fast alternating hand movements, and heel-shin slide. The total score of the 8 items ranges from 0 (normal cerebellar function) to 40 (not able to perform any of the test items).

    Time frame: Baseline to 6 and 12 months

  11. Change From Baseline in the Time Spent to Complete the Nine-Hole Peg Test (9HPT)

    The 9HPT test is a direct and simple measurement of fine motor coordination function, eye/hand coordination, and the ability to follow a simple direction. The 9HPT is a timed test in which nine pegs are inserted and removed from nine holes in the pegboard. Both hands are tested starting with the dominant hand. The time spent in completing the 9 HPT using each hand was recorded.

    Time frame: Baseline to 6 and 12 months

  12. Percentage of Participants Within Each Severity Category of the Clinical Global Impression Scale of Severity (CGI-S)

    The CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment. A rating of 1 is considered normal, or with the least severe symptoms, a rating of 7 is extremely ill, or the worst symptoms. Scores thus range from 1-7 with lower scores indicating less severe disease.

    Time frame: Months 6 and 12

  13. Percentage of Participants Within Each Category of the Clinical Global Impression Scale of Improvement (CGI-I)

    The CGI-I is a 7-point scale that rates total improvement of participant's condition. The clinician rates the participants from 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, or 7=Very much worse. Scores thus range from 1-7 with lower scores indicating greater improvement.

    Time frame: Months 6 and 12

07

Results

Posted Jun 9, 2023

Participant flow

The study was conducted at 14 sites in Denmark, France, Germany, Italy, Poland, Spain, Switzerland, United Kingdom, and United States.

Single Dose Treatment Period
Participant flow — Single Dose Treatment Period
MilestoneArimoclomol Single PK DoseArimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)
Started2800
Completed2700
Not completed100
Withdrew: Screening failure100
Continuous Treatment Period
Participant flow — Continuous Treatment Period
MilestoneArimoclomol Single PK DoseArimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)
Started03416
Completed02715
Not completed071
Withdrew: Early escape020
Withdrew: Participant's parents/legal guardian have withdrawn informed consent010
Withdrew: Safety reasons030
Withdrew: Death010
Withdrew: Participant meets criteria for imp administration to be stopped and subsequent withdrawal001

Outcome measures

PrimaryChange From Baseline in the Niemann-Pick Disease Type C (NPC) Disease Severity Assessed Based on the 5-domain NPCCSS Total Scores

NPC disease severity was assessed based on the 5-domain NPC Clinical Severity Scale (NPCCSS). The 5-domain NPCCSS focuses on domains identified by participants, caregivers, and NPC experts as the most clinically relevant when assessing disease progression in NPC: Ambulation, fine motor skills, swallow, cognition, and speech. The scale is derived from the original 17-domain NPCCSS. Each domain is rated on a scale of 0-5 based on clinical assessments, observations, and interviews with participants/caregiver. The total score is a sum of the score of each of the 5 domains and ranges from 0-25, with a higher score indicating more severe clinical impairment.

Time frame:
Baseline to Month 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Niemann-Pick Disease Type C (NPC) Disease Severity Assessed Based on the 5-domain NPCCSS Total Scores
score on a scaleArimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)
Change From Baseline in the Niemann-Pick Disease Type C (NPC) Disease Severity Assessed Based on the 5-domain NPCCSS Total Scores0.76 (-0.05 to 1.56)2.15 (1.05 to 3.25)
Statistical analysis
  • Arimoclomol (12-month Double-blind Phase) vs Placebo (12-month Double-blind Phase) · GLMM for Repeated Measures · p = 0.0456 · Least square (ls) mean difference: -1.40 · 95% CI -2.76 to -0.03
SecondaryPercentage of Responders in Clinical Global Impression Scale of Improvement (CGI-I) - Defined as Percentage of Participants Where the CGI-I Score Remains Stable or Shows Improvement (This Outcome Measure Was Considered Co-primary by the FDA)

The CGI-I is a 7-point scale that rates total improvement of participant's condition. The clinician rates the participants from 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, or 7=Very much worse. Scores thus range from 1-7 with lower scores indicating greater improvement. Responders were the participants with a score of 1 or 2 at Month 12.

Time frame:
Month 12
Reported as:
Number · percentage of responders
Percentage of Responders in Clinical Global Impression Scale of Improvement (CGI-I) - Defined as Percentage of Participants Where the CGI-I Score Remains Stable or Shows Improvement (This Outcome Measure Was Considered Co-primary by the FDA)
percentage of respondersArimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)
Percentage of Responders in Clinical Global Impression Scale of Improvement (CGI-I) - Defined as Percentage of Participants Where the CGI-I Score Remains Stable or Shows Improvement (This Outcome Measure Was Considered Co-primary by the FDA)58.856.3
Statistical analysis
  • Arimoclomol (12-month Double-blind Phase) vs Placebo (12-month Double-blind Phase) · Chi-squared Test · p = 1.0000
SecondaryPercentage of Responders in 5-domain NPCCSS - Defined as Participants Where the 5-domain NPCCSS Score Remains Stable or Improves as Compared to Baseline

NPC disease severity was assessed based on the 5-domain NPC Clinical Severity Scale (NPCCSS). The 5-domain NPCCSS focuses on domains identified by participants, caregivers, and NPC experts as the most clinically relevant when assessing disease progression in NPC: Ambulation, fine motor skills, swallow, cognition, and speech. The scale is derived from the original 17-domain NPCCSS. Each domain is rated on a scale of 0-5 based on clinical assessments, observations, and interviews with participants/caregiver. The total score is a sum of the score of each of the 5 domains and ranges from 0-25, with a higher score indicating more severe clinical impairment. Stable was defined as a participant's total score for the 5 domains being the same at month 12 as at baseline. Improvement was defined as a participant's total score at month 12 being lower than at baseline.

Time frame:
Baseline to Month 12
Reported as:
Number · percentage of responders
Percentage of Responders in 5-domain NPCCSS - Defined as Participants Where the 5-domain NPCCSS Score Remains Stable or Improves as Compared to Baseline
percentage of respondersArimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)
Percentage of Responders in 5-domain NPCCSS - Defined as Participants Where the 5-domain NPCCSS Score Remains Stable or Improves as Compared to Baseline50.037.5
Statistical analysis
  • Arimoclomol (12-month Double-blind Phase) vs Placebo (12-month Double-blind Phase) · Chi-squared Test · p = 0.5456
SecondaryTime to Worsening

Time to worsening was defined as the time until the participant reached the predefined minimal clinically important difference (MCID) of 2 points compared to baseline on the 5-domain NPC Clinical Severity Scale (NPCCSS). The 5-domain NPCCSS focuses on domains identified by participants, caregivers, and NPC experts as the most clinically relevant when assessing disease progression in NPC: Ambulation, fine motor skills, swallow, cognition, and speech. The scale is derived from the original 17-domain NPCCSS. Each domain is rated on a scale of 0-5 based on clinical assessments, observations, and interviews with participants/caregiver. The total score is a sum of the score of each of the 5 domains and ranges from 0-25, with a higher score indicating more severe clinical impairment. The values reported per group are the 25th percentile Kaplan-Meier estimates and 95% confidence interval.

Time frame:
Baseline to Month 12
Reported as:
Number · months
Time to Worsening
monthsArimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)
Time to Worsening5.2 (2.9 to 12.0)5.5 (1.0 to 6.5)
Statistical analysis
  • Arimoclomol (12-month Double-blind Phase) vs Placebo (12-month Double-blind Phase) · Log-Rank Test · p = 0.8021
SecondaryPercentage of Participants With Worsening

Worsening was defined as participants that have reached the predefined MCID of 2 points on their 5-domain NPC Clinical Severity Scale (NPCCSS). The 5-domain NPCCSS focuses on domains identified by participants, caregivers, and NPC experts as the most clinically relevant when assessing disease progression in NPC: Ambulation, fine motor skills, swallow, cognition, and speech. The scale is derived from the original 17-domain NPCCSS. Each domain is rated on a scale of 0-5 based on clinical assessments, observations, and interviews with participants/caregiver. The total score is a sum of the score of each of the 5 domains and ranges from 0-25, with a higher score indicating more severe clinical impairment.

Time frame:
Months 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Worsening
percentage of participantsArimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)
Worsening at Month 635.350.0
Worsening at Month 1244.143.8
Statistical analysis
  • Arimoclomol (12-month Double-blind Phase) vs Placebo (12-month Double-blind Phase) · Fisher's Exact Test · p = 0.3662
  • Arimoclomol (12-month Double-blind Phase) vs Placebo (12-month Double-blind Phase) · Fisher's Exact Test · p = 1.0000
SecondaryChange From Baseline in 17-domain NPCCSS Apart From Hearing Domains (i.e. Hearing and Auditory Brainstem Response)

The NPC Clinical Severity Scale (NPCCSS) is a disease-specific, clinician-reported outcome measure developed to characterize and quantify NPC disease progression. The 17-domain NPCCSS includes clinical signs and symptoms in nine major and eight minor domains, which are rated on scales of 0-5 (for the major domains) or 0-2 (for the minor domains). The total score is the sum of the score of each of the 17 domains and ranges from 0 to 61, with a high score indicating a more severe clinical impairment.

Time frame:
Baseline to 6 and 12 months
Reported as:
Least squares mean · score on a scale
Change From Baseline in 17-domain NPCCSS Apart From Hearing Domains (i.e. Hearing and Auditory Brainstem Response)
score on a scaleArimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)
Change at Month 60.53 (-0.85 to 1.90)2.22 (0.33 to 4.10)
Change at Month 121.20 (-0.40 to 2.79)2.81 (0.75 to 4.87)
Statistical analysis
  • Arimoclomol (12-month Double-blind Phase) vs Placebo (12-month Double-blind Phase) · ANCOVA · p = 0.1546 · Ls mean difference: -1.69 · 95% CI -4.04 to 0.66
  • Arimoclomol (12-month Double-blind Phase) vs Placebo (12-month Double-blind Phase) · ANCOVA · p = 0.2199 · Ls mean difference: -1.61 · 95% CI -4.24 to 1.01
SecondaryChange From Baseline in 5-domain NPCCSS Score

The 5-domain NPC Clinical Severity Scale (NPCCSS) focuses on domains identified by participants, caregivers, and NPC experts as the most clinically relevant when assessing disease progression in NPC: Ambulation, fine motor skills, swallow, cognition, and speech. The scale is derived from the original 17-domain NPCCSS. Each domain is rated on a scale of 0-5 based on clinical assessments, observations, and interviews with participants/caregiver. The total score is a sum of the score of each of the 5 domains and ranges from 0-25, with a higher score indicating more severe clinical impairment.

Time frame:
Baseline to 6 months
Reported as:
Least squares mean · score on a scale
Change From Baseline in 5-domain NPCCSS Score
score on a scaleArimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)
Change From Baseline in 5-domain NPCCSS Score0.48 (-0.05 to 1.02)1.60 (0.86 to 2.34)
Statistical analysis
  • Arimoclomol (12-month Double-blind Phase) vs Placebo (12-month Double-blind Phase) · ANCOVA · p = 0.0188 · Least square (ls) mean difference: -1.11 · 95% CI -2.03 to -0.19
SecondaryChanges From Baseline in Each Individual Domain of the NPCCSS

The NPC Clinical Severity Scale (NPCCSS) is a disease-specific, clinician-reported outcome measure developed to characterize and quantify disease progression. The 17-domain NPCCSS includes clinical signs and symptoms in nine major (ambulation, cognition, eye movement, fine motor, hearing, memory, seizures, speech, swallowing,) and eight minor (auditory brainstem response, behavior, gelastic cataplexy, hyperreflexia, incontinence, narcolepsy, psychiatric, respiratory problems) domains, which are rated on scales of 0-5 (for the major domains) or 0-2 (for the minor domains). A higher score indicates a more severe clinical impairment.

Time frame:
Baseline to 6 and 12 months
Reported as:
Mean · score on a scale
Changes From Baseline in Each Individual Domain of the NPCCSS
score on a scaleArimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)
Ambulation: Baseline2.5 ± 1.62.2 ± 1.6
Ambulation: Change at Month 60.1 ± 0.40.3 ± 1.0
Ambulation: Change at Month 120.3 ± 0.50.3 ± 0.9
Speech: Baseline2.2 ± 1.61.6 ± 1.2
Speech: Change at Month 60.1 ± 0.50.1 ± 0.3
Speech: Change at Month 12-0.2 ± 1.00.3 ± 0.8
Swallow: Baseline1.9 ± 1.71.3 ± 1.7
Swallow: Change at Month 60.1 ± 1.10.4 ± 1.0
Swallow: Change at Month 120.1 ± 1.10.6 ± 1.0
Fine Motor Skills: Baseline2.8 ± 1.81.9 ± 1.8
Fine Motor Skills: Change at Month 60.1 ± 0.70.5 ± 1.1
Fine Motor Skills: Change at Month 120.2 ± 0.80.6 ± 1.3
Cognition: Baseline2.8 ± 1.32.5 ± 1.5
Cognition: Change at Month 60.2 ± 0.50.3 ± 0.8
Cognition: Change at Month 120.3 ± 0.60.1 ± 0.6
Eye Movement: Baseline2.2 ± 1.22.1 ± 1.1
Eye Movement: Change at Month 60.0 ± 0.6-0.1 ± 0.7
Eye Movement: Change at Month 120.2 ± 0.9-0.1 ± 0.6
Memory: Baseline1.9 ± 1.41.3 ± 1.5
Memory: Change at Month 60.1 ± 0.50.2 ± 1.1
Memory: Change at Month 120.1 ± 0.50.3 ± 0.8
Seizures: Baseline1.9 ± 1.91.3 ± 1.8
Seizures: Change at Month 6-0.1 ± 0.80.0 ± 1.5
Seizures: Change at Month 120.3 ± 0.8-0.1 ± 1.7
Hearing: Baseline0.4 ± 1.00.0 ± 0.0
Hearing: Change at Month 6-0.2 ± 0.80.0 ± 0.0
Hearing: Change at Month 120.0 ± 0.00.3 ± 0.8
Auditory Brainstem Response: Baseline0.2 ± 0.40.1 ± 0.4
Auditory Brainstem Response: Change at Month 60.0 ± 0.00.2 ± 0.4
Auditory Brainstem Response: Change at Month 120.0 ± 0.00.0 ± 0.0
Behavior: Baseline0.4 ± 0.60.4 ± 0.6
Behavior: Change at Month 60.0 ± 0.5-0.1 ± 0.5
Behavior: Change at Month 120.1 ± 0.6-0.2 ± 0.4
Gelastic Cataplexy: Baseline0.8 ± 0.90.4 ± 0.8
Gelastic Cataplexy: Change at Month 60.1 ± 0.50.3 ± 0.6
Gelastic Cataplexy: Change at Month 120.2 ± 0.60.3 ± 0.6
Hyperreflexia: Baseline1.0 ± 0.71.1 ± 0.9
Hyperreflexia: Change at Month 6-0.0 ± 0.50.2 ± 0.6
Hyperreflexia: Change at Month 120.1 ± 0.70.1 ± 0.5
Incontinence: Baseline1.0 ± 0.80.8 ± 0.9
Incontinence: Change at Month 6-0.1 ± 0.40.1 ± 0.5
Incontinence: Change at Month 12-0.0 ± 0.40.1 ± 0.9
Narcolepsy (NARCO): Baseline0.1 ± 0.40.3 ± 0.7
Narcolepsy (NARCO): Change at Month 60.0 ± 0.4-0.1 ± 0.3
Narcolepsy (NARCO): Change at Month 12-0.1 ± 0.4-0.1 ± 0.3
Psychiatric: Baseline0.1 ± 0.40.1 ± 0.5
Psychiatric: Change at Month 6-0.0 ± 0.30.1 ± 0.6
Psychiatric: Change at Month 120.0 ± 0.30.0 ± 0.4
Respiratory: Baseline0.1 ± 0.30.0 ± 0.0
Respiratory: Change at Month 60.0 ± 0.50.1 ± 0.3
Respiratory: Change at Month 120.1 ± 0.50.2 ± 0.4
SecondaryChange From Baseline in the NPC Clinical Database (NPC-CDB) Score (Modified "Stampfer Score")

The NPC Clinical Database (NPC-cdb) score aims to reflect the current clinical status of the participant. The NPC-cdb score represents both historical symptoms and a current status. The test consists of ten areas: visceral signs, development, motor function, ocular-motor abnormalities, seizures/cataplexy/narcolepsy, cognitive abilities and memory, behavioral and psychiatric abnormalities, speech, hearing, and abilities in daily life. The current status score is a severity-weighted sum of 72 symptoms considered as disease-relevant at the time of assessment. Each symptom contributes with a score between 1 and 5, the maximum score is 125. An increase in score reflects a reduction in the participant's abilities.

Time frame:
Baseline to 6 and 12 months
Reported as:
Least squares mean · score on a scale
Change From Baseline in the NPC Clinical Database (NPC-CDB) Score (Modified "Stampfer Score")
score on a scaleArimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)
Change at Month 6-0.38 (-3.30 to 2.54)4.71 (0.49 to 8.93)
Change at Month 121.85 (-2.16 to 5.86)4.88 (-0.63 to 10.39)
Statistical analysis
  • Arimoclomol (12-month Double-blind Phase) vs Placebo (12-month Double-blind Phase) · ANCOVA · p = 0.0536 · Ls mean difference: -5.09 · 95% CI -10.26 to 0.08
  • Arimoclomol (12-month Double-blind Phase) vs Placebo (12-month Double-blind Phase) · ANCOVA · p = 0.3785 · Ls mean difference: -3.03 · 95% CI -9.90 to 3.85
SecondaryPercentage of Participants With Change From Baseline in Quality of Life (EQ-5D-Y)

The EQ-5D-Y descriptive system includes 5 descriptive items: Mobility, self-care, doing usual activities, having pain or discomfort, and feeling anxiety or depressed. Each dimension has 3 levels: No problems, some problems, and a lot of problems. The change in the 5 individual items of the EQ-5D-Y per participant was explored by using the pareto principle at 6 and 12 months to show the number (%) of participants who felt: * Better (better on at least one dimension and no worse in any other dimension), * Worse (worse in at least one dimension, and no better in any other dimension)

Time frame:
Baseline to 6 and 12 months
Reported as:
Number · percentage of participants
Percentage of Participants With Change From Baseline in Quality of Life (EQ-5D-Y)
percentage of participantsArimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)
Better: Change at Month 616.726.7
Worse: Change at Month 640.046.7
Better: Change at Month 1225.940.0
Worse: Change at Month 1244.420.0
Statistical analysis
  • Arimoclomol (12-month Double-blind Phase) vs Placebo (12-month Double-blind Phase) · Chi-squared Test · p = 0.6951
  • Arimoclomol (12-month Double-blind Phase) vs Placebo (12-month Double-blind Phase) · Chi-squared Test · p = 0.7542
  • Arimoclomol (12-month Double-blind Phase) vs Placebo (12-month Double-blind Phase) · Chi-squared Test · p = 0.4880
  • Arimoclomol (12-month Double-blind Phase) vs Placebo (12-month Double-blind Phase) · Chi-squared Test · p = 0.1804
SecondaryChange From Baseline in the Scale for Assessment and Rating of Ataxia (SARA) Score

The SARA included eight items reflecting neurologic manifestations of cerebellar ataxia. The test provides a direct and simple description of motor function in a participant. The test consists of 8 test items: gait, stance, sitting, speech disturbance, finger chase, nose-finger test, fast alternating hand movements, and heel-shin slide. The total score of the 8 items ranges from 0 (normal cerebellar function) to 40 (not able to perform any of the test items).

Time frame:
Baseline to 6 and 12 months
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Scale for Assessment and Rating of Ataxia (SARA) Score
score on a scaleArimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)
Change at 6 months0.79 (-0.16 to 1.75)0.05 (-1.29 to 1.40)
Change at 12 months1.06 (-0.17 to 2.29)0.78 (-0.90 to 2.47)
Statistical analysis
  • Arimoclomol (12-month Double-blind Phase) vs Placebo (12-month Double-blind Phase) · ANCOVA · p = 0.3710 · Ls mean difference: 0.74 · 95% CI -0.92 to 2.40
  • Arimoclomol (12-month Double-blind Phase) vs Placebo (12-month Double-blind Phase) · ANCOVA · p = 0.7899 · Ls mean difference: 0.28 · 95% CI -1.82 to 2.37
SecondaryChange From Baseline in the Time Spent to Complete the Nine-Hole Peg Test (9HPT)

The 9HPT test is a direct and simple measurement of fine motor coordination function, eye/hand coordination, and the ability to follow a simple direction. The 9HPT is a timed test in which nine pegs are inserted and removed from nine holes in the pegboard. Both hands are tested starting with the dominant hand. The time spent in completing the 9 HPT using each hand was recorded.

Time frame:
Baseline to 6 and 12 months
Reported as:
Least squares mean · seconds
Change From Baseline in the Time Spent to Complete the Nine-Hole Peg Test (9HPT)
secondsArimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)
Dominant Hand: Change at 6 months1.54 (-24.98 to 28.06)11.88 (-20.88 to 44.64)
Non-dominant Hand: Change at 6 months0.60 (-27.25 to 28.45)16.46 (-17.07 to 50.00)
Dominant Hand: Change at 12 months-3.29 (-15.56 to 8.98)-6.49 (-20.34 to 7.37)
Non-dominant Hand: Change at 12 months11.68 (-14.89 to 38.25)17.59 (-13.24 to 48.42)
Statistical analysis
  • Arimoclomol (12-month Double-blind Phase) vs Placebo (12-month Double-blind Phase) · ANCOVA · p = 0.6195 · Ls mean difference: -10.34 · 95% CI -53.01 to 32.33
  • Arimoclomol (12-month Double-blind Phase) vs Placebo (12-month Double-blind Phase) · ANCOVA · p = 0.4693 · Ls mean difference: -15.87 · 95% CI -60.73 to 29.00
  • Arimoclomol (12-month Double-blind Phase) vs Placebo (12-month Double-blind Phase) · ANCOVA · p = 0.7283 · Ls mean difference: 3.20 · 95% CI -15.71 to 22.12
  • Arimoclomol (12-month Double-blind Phase) vs Placebo (12-month Double-blind Phase) · ANCOVA · p = 0.7708 · Ls mean difference: -5.91 · 95% CI -47.54 to 35.72
SecondaryPercentage of Participants Within Each Severity Category of the Clinical Global Impression Scale of Severity (CGI-S)

The CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment. A rating of 1 is considered normal, or with the least severe symptoms, a rating of 7 is extremely ill, or the worst symptoms. Scores thus range from 1-7 with lower scores indicating less severe disease.

Time frame:
Months 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants Within Each Severity Category of the Clinical Global Impression Scale of Severity (CGI-S)
percentage of participantsArimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)
Month 6: Normal, not ill at all00
Month 6: Borderline ill10.314.3
Month 6: Mildly ill27.628.6
Month 6: Moderately ill10.335.7
Month 6: Markedly ill31.00
Month 6: Severely ill20.714.3
Month 6: Most extremely ill participants07.1
Month 12: Normal, not ill at all00
Month 12: Borderline ill7.46.7
Month 12: Mildly ill29.626.7
Month 12: Moderately ill11.133.3
Month 12: Markedly ill29.66.7
Month 12: Severely ill22.226.7
Month 12: Most extremely ill participants00
SecondaryPercentage of Participants Within Each Category of the Clinical Global Impression Scale of Improvement (CGI-I)

The CGI-I is a 7-point scale that rates total improvement of participant's condition. The clinician rates the participants from 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, or 7=Very much worse. Scores thus range from 1-7 with lower scores indicating greater improvement.

Time frame:
Months 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants Within Each Category of the Clinical Global Impression Scale of Improvement (CGI-I)
percentage of participantsArimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)
Month 6: Very Much Improved3.40
Month 6: Much Improved00
Month 6: Minimally Improved24.125.0
Month 6: No Change37.925.0
Month 6: Minimally Worse27.633.3
Month 6: Much Worse6.916.7
Month 6: Very Much Worse00
Month 12: Very Much Improved00
Month 12: Much Improved3.76.7
Month 12: Minimally Improved18.533.3
Month 12: No Change51.920.0
Month 12: Minimally Worse14.813.3
Month 12: Much Worse7.426.7
Month 12: Very Much Worse3.70

Adverse events

Collected over From first dose of study drug up to last dose of blinded study treatment (Month 12). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arimoclomol Single PK Dose0/28 (0%)2/28 (7.1%)4/28 (14.3%)
Arimoclomol (12-month Double-blind Phase)1/34 (2.9%)5/34 (14.7%)30/34 (88.2%)
Placebo (12-month Double-blind Phase)0/16 (0%)6/16 (37.5%)13/16 (81.3%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventArimoclomol Single PK DoseArimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)
PneumoniaInfections and infestations1/280/342/16
EpilepsyNervous system disorders0/280/342/16
DiarrhoeaGastrointestinal disorders0/280/341/16
Lower Respiratory Tract InfectionInfections and infestations0/280/341/16
Craniocerebral InjuryInjury, poisoning and procedural complications0/280/341/16
LacerationInjury, poisoning and procedural complications0/280/341/16
HypophagiaMetabolism and nutrition disorders0/280/341/16
Foot DeformityMusculoskeletal and connective tissue disorders0/280/341/16
Respiratory Tract InfectionInfections and infestations0/280/341/16
UrticariaSkin and subcutaneous tissue disorders0/282/340/16
Most frequent other events
Showing 10 of 128
Most frequent other events
EventArimoclomol Single PK DoseArimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)
VomitingGastrointestinal disorders0/288/344/16
NasopharyngitisInfections and infestations0/282/344/16
ConstipationGastrointestinal disorders0/287/343/16
DiarrhoeaGastrointestinal disorders0/287/342/16
PyrexiaGeneral disorders1/286/343/16
Upper Respiratory Tract InfectionInfections and infestations1/286/341/16
RhinitisInfections and infestations0/285/342/16
Weight DecreasedInvestigations0/285/340/16
BronchitisInfections and infestations0/284/342/16
Ear InfectionInfections and infestations0/280/342/16

Baseline characteristics

Full Analysis Set (FAS) included those participants who were randomized and who had received at least one dose of randomized treatment medication.

Age, Continuous
Age, Continuous(years)Arimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)Total
Mean11.5 ± 5.410.2 ± 4.111.1 ± 5.0
Sex: Female, Male
Sex: Female, Male(Participants)Arimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)Total
Female17926
Male17724
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)Total
Hispanic or Latino202
Not Hispanic or Latino321648
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)Total
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander011
Black or African American000
White321345
More than one race000
Unknown or Not Reported112
Age at Diagnosis of First Neurological Symptom
Age at Diagnosis of First Neurological Symptom(years)Arimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)Total
Mean5.05 ± 3.435.22 ± 3.875.10 ± 3.54
5-domain Niemann-Pick Disease Type C Clinical Severity Scale (NPCCSS) Score
5-domain Niemann-Pick Disease Type C Clinical Severity Scale (NPCCSS) Score(score on a scale)Arimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)Total
Mean12.1 ± 6.99.4 ± 6.411.2 ± 6.8
17-domain NPCCSS Except Hearing Domains
17-domain NPCCSS Except Hearing Domains(score on a scale)Arimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)Total
Mean21.2 ± 11.517.2 ± 11.319.9 ± 11.4
Participants Currently Treated With Miglustat
Participants Currently Treated With Miglustat(Participants)Arimoclomol (12-month Double-blind Phase)Placebo (12-month Double-blind Phase)Total
Yes261339
No8311
08

Study locations

14 sites
  • UCSF Benioff Children's Hospital Oakland
    Oakland, California 94609, United States
  • Mayo Clinic Children's Center
    Rochester, Minnesota 55905, United States
  • University Hospital Copenhagen (Rigshospitalet)
    Copenhagen, 2100, Denmark
  • CHU de Montpellier
    Montpellier, 34295 Montpellier Cedex 5, France
  • Hôpital Trousseau
    Paris, 75571 PARIS Cedex 12, France
  • Villa Metabolica, Universitätsmedizin Mainz
    Mainz, 55131, Germany
  • Dr. von Haunersches Kinderspital der Universität München
    Munich, 80337, Germany
  • Ospedale Pediatrico Bambino Gesù
    Rome, 00165, Italy
  • Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" di Udin
    Udine, 33100, Italy
  • The Children´s Memorial Istitute Warsaw
    Warsaw, 04-730, Poland
  • Hospital Vall D'Hebron
    Barcelona, 08035, Spain
  • INSELSPITAL University Hospital Bern
    Bern, CH-3010, Switzerland
  • Birmingham Children's Hospital
    Birmingham, B4 6NH, United Kingdom
  • Great Ormond Street Hospital
    London, WC1N 3JH, United Kingdom
09

References and documents

Publications

  • Patterson MC, Lloyd-Price L, Guldberg C, Doll H, Burbridge C, Chladek M, iDali C, Mengel E, Symonds T. Validation of the 5-domain Niemann-Pick type C Clinical Severity Scale. Orphanet J Rare Dis. 2021 Feb 12;16(1):79. doi: 10.1186/s13023-021-01719-2. PubMed 33579322 ↗
  • Mengel E, Patterson MC, Da Riol RM, Del Toro M, Deodato F, Gautschi M, Grunewald S, Gronborg S, Harmatz P, Heron B, Maier EM, Roubertie A, Santra S, Tylki-Szymanska A, Day S, Andreasen AK, Geist MA, Havnsoe Torp Petersen N, Ingemann L, Hansen T, Blaettler T, Kirkegaard T, I Dali C. Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment. J Inherit Metab Dis. 2021 Nov;44(6):1463-1480. doi: 10.1002/jimd.12428. Epub 2021 Sep 7. PubMed 34418116 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2016 to primary completion in Jun 2018, 24 months.

Results were first posted in Jun 2023, 4 years 11 months after primary completion. A results delay was requested in May 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2015
First posted
Nov 23, 2015
StartActual
Jun 14, 2016
Primary completionActual
Jun 25, 2018
CompletionActual
Oct 31, 2024
Results delay requested
May 14, 2019
Results first posted
Jun 9, 2023
Last update
Nov 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02612129
Lead sponsor
ZevraDenmark
Responsible party
Sponsor
First posted
Nov 23, 2015
Start date
Jun 14, 2016
Primary completion
Jun 25, 2018
Completion
Oct 31, 2024
Results posted
Jun 9, 2023
Last update
Nov 29, 2024

Study contacts

Karl-Eugen Mengel
principal investigator · SphinCS GmbH, Hochheim, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arimoclomol

Start the discussion